Canopy Growth Corporation (CGC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate company logo of Canopy Growth Corp (CGC)

Canopy Growth (CGC) management is operating in a state of constant crisis management, striving to regain shareholder trust following prolonged equity dilution. Business efficiency is improving through the implementation of robotic irrigation and climate control systems in greenhouses. This chart reflects that current share prices place the EV/EBITDA multiple at 0.00. Primary medical plant cultivation capacities are based in Canada, leveraging support from beverage industry behemoths.

Canopy Growth Corp - CGC Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

canopygrowth.com - analytical breakdowns and key metrics (CGC)

- market price and analyst price targets:
Initial company analysis:CGC (Tweed)
Original product of Canopy Growth Corporation

Canopy Growth's transition to a royalty model is designed to reduce reliance on capital-intensive greenhouses. The EV/EBITDA multiple quantifies this process by comparing enterprise value—market capitalization plus debt—against operating profit before taxes. Low values may signal either an undervaluation or a critical level of corporate leverage. By analyzing the dynamic EV/EBITDA metric of Canopy Growth, an investor determines how efficiently the assets generate cash flow.

Direct competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Indivior Group INDV|Business Value to Operating Income Before Depreciation COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|hightideinc.com (HITI) - Enterprise Value to EBITDA Ratio|ACB: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Achieve Life Sciences Inc.|SKYE (Skye Bioscience, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Anebulo Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization InterCure Ltd. (INCR)|nutriband.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nasus Pharma NSRX|India Globalization Capital (IGC) - Company Value to EBITDA|MIRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio FLGC|IMCC (imcannabis.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Adial Pharmaceuticals, Inc. (ADIL)|Enterprise Value to EBITDA Ratio ARTL|ENSC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TTNP|Greenlane Corp (GNLN) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization InMed Pharmaceuticals INM|Business Value to Operating Income Before Depreciation AKAN|ENVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Bright Green|HPCO (Hempacco) - Enterprise Value to EBITDA Ratio